Á. Sebők

Weight reduction added to CPAP decreases blood pressure and triglyceride level in OSA: Systematic review and meta‐analysis

P. Hegyi, B. Faludi, Z. Szakács, 2022, Clinical and translational science.

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

B. Byrne, A. Pestronk, M. Tarnopolsky, 2021, The Lancet Neurology.

Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease

L. Kerényi, Z. Almássy, M. Molnár, 2021, Life.

Cortical involvement during myotonia in myotonic dystrophy: an fMRI study

P. Bogner, J. Janszky, S. Komoly, 2015, Acta neurologica Scandinavica.

Elevated FGF 21 in myotonic dystrophy type 1 and mitochondrial diseases

S. Komoly, V. Karcagi, K. Fülöp, 2017, Muscle & nerve.

Inactivation of Rho Signaling Pathway Promotes CNS Axon Regeneration

N. Leclerc, A. Fournier, G. Tigyi, 1999, The Journal of Neuroscience.

[The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].

L. Kerényi, Z. Almássy, L. Dézsi, 2020, Ideggyogyaszati szemle.